Amgen has terminated its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab, signaling a strategic shift towards expanding its dermatology and autoimmune pipeline. This decision allows Kyowa Kirin to take full control over the rocatinlimab program, while Amgen reallocates resources towards promising projects like the monthly injectable obesity treatment MariTide. Despite this collaboration ending, Amgen recently reported strong quarterly revenues of $9.56 billion, leading to a 16.4% increase in its stock price, as investor optimism grows amid an evolving oncology pipeline and new research initiatives. However, the company faces potential legal risks from a lawsuit regarding drug pricing, which may pose challenges ahead.
“Kyowa Kirin (KYKOF) announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. This business decision is the result of a strategic portfolio prioritization by Amgen (AMGN).”
“Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization.”
“Amgen (NasdaqGS:AMGN) has ended its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab. The decision is tied to portfolio prioritization and returns full program control to Kyowa Kirin.”
“The move signals a shift in Amgen’s focus within its dermatology and autoimmune pipeline.”
“Looking ahead, the key question is how Amgen reallocates R&D capital and internal resources now that rocatinlimab is off the table.”
“Amgen has terminated a licensing and collaboration agreement signed in 2021 with Japanese pharma Kyowa Kirin regarding the development of the biologic roctinlimab for atopic dermatitis. The company noted that Amgen ended the agreement due to a strategic portfolio prioritization.”
“Amgen reported revenues of $9.56 billion, up 12.4% year on year. This result surpassed analysts’ expectations by 6.6%.”
“Overall, it was a very strong quarter as it also put up a solid beat of analysts’ revenue estimates and full-year revenue guidance beating analysts’ expectations.”
“The stock is up 15.2% since reporting and currently trades at $341.75.”
“Amgen is developing a promising GLP-1 drug, MariTide, which is an injectable treatment that can be taken just once a month. Mounjaro and Zepbound are both weekly injectables.”
“If MariTide, which is currently in phase 3 trials, ends up obtaining approval, there could be a ton of upside for Amgen's stock.”
“Amgen is a cheap buy in comparison to Eli Lilly, and with a possible catalyst that could drive its share price much higher, it could make for an appealing healthcare stock to buy right now.”